What is Tiamat?
Tiamat Sciences operates at the intersection of biotechnology and sustainable manufacturing. The company specializes in the production of animal-free proteins, utilizing a sophisticated plant molecular farming platform that offers a scalable, cost-effective alternative to conventional bioreactor-based methods. By engineering plants to act as biological factories, Tiamat provides high-value proteins for diverse applications, ranging from cellular agriculture to therapeutic development.
The company's market position is defined by its commitment to reducing the environmental footprint of protein production. As the demand for ethical and sustainable raw materials increases, Tiamat's proprietary technology serves as a foundational layer for next-generation food tech and biotech enterprises. Their Durham-based facility serves as the hub for ongoing innovation, where the team continues to refine their molecular farming techniques to improve yield and purity.
How much funding has Tiamat raised?
Tiamat has raised a total of $5.4M across 1 funding round:
Angel/Seed
$5.4M
Angel/Seed (2023): $5.4M with participation from True Ventures and SeedFolio
Key Investors in Tiamat
True Ventures
True Ventures is a founder-first venture capital firm that partners with creative teams at the earliest stages, providing capital, guidance, and a strong community to help build enduring technology and artificial intelligence-driven companies.
SeedFolio
SeedFolio is a San Diego-based venture capital firm that focuses on early investments in innovative teams working on technologies aimed at combating disease and environmental challenges.
What's next for Tiamat?
Looking ahead, Tiamat Sciences is poised to leverage its recent capital infusion to accelerate the industrialization of its molecular farming platform. The strategic roadmap likely includes expanding production capacity to meet the growing demand for animal-free ingredients and deepening partnerships with downstream manufacturers in the food and medical industries.
As the company moves beyond its initial seed-stage milestones, the focus will shift toward optimizing unit economics and securing regulatory approvals for its protein products. By maintaining a rigorous approach to scientific development and operational scaling, Tiamat is well-positioned to disrupt traditional protein supply chains, offering a cleaner, more efficient alternative that aligns with global sustainability goals and the increasing consumer preference for ethically sourced biotechnology products.
